IBDEI3AG ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,52483,0)
 ;;=E10.65^^194^2539^14
 ;;^UTILITY(U,$J,358.3,52483,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52483,1,3,0)
 ;;=3^DM Type 1 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,52483,1,4,0)
 ;;=4^E10.65
 ;;^UTILITY(U,$J,358.3,52483,2)
 ;;=^5002623
 ;;^UTILITY(U,$J,358.3,52484,0)
 ;;=E10.69^^194^2539^29
 ;;^UTILITY(U,$J,358.3,52484,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52484,1,3,0)
 ;;=3^DM Type 1 w/ Oth Spec Compl
 ;;^UTILITY(U,$J,358.3,52484,1,4,0)
 ;;=4^E10.69
 ;;^UTILITY(U,$J,358.3,52484,2)
 ;;=^5002624
 ;;^UTILITY(U,$J,358.3,52485,0)
 ;;=E10.8^^194^2539^33
 ;;^UTILITY(U,$J,358.3,52485,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52485,1,3,0)
 ;;=3^DM Type 1 w/ Unspec Compl
 ;;^UTILITY(U,$J,358.3,52485,1,4,0)
 ;;=4^E10.8
 ;;^UTILITY(U,$J,358.3,52485,2)
 ;;=^5002625
 ;;^UTILITY(U,$J,358.3,52486,0)
 ;;=E10.9^^194^2539^34
 ;;^UTILITY(U,$J,358.3,52486,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52486,1,3,0)
 ;;=3^DM Type 1 w/o Compl
 ;;^UTILITY(U,$J,358.3,52486,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,52486,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,52487,0)
 ;;=E10.620^^194^2539^5
 ;;^UTILITY(U,$J,358.3,52487,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52487,1,3,0)
 ;;=3^DM Type 1 w/ Diab Dermatitis
 ;;^UTILITY(U,$J,358.3,52487,1,4,0)
 ;;=4^E10.620
 ;;^UTILITY(U,$J,358.3,52487,2)
 ;;=^5002615
 ;;^UTILITY(U,$J,358.3,52488,0)
 ;;=E10.36^^194^2539^4
 ;;^UTILITY(U,$J,358.3,52488,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52488,1,3,0)
 ;;=3^DM Type 1 w/ Diab Cataract
 ;;^UTILITY(U,$J,358.3,52488,1,4,0)
 ;;=4^E10.36
 ;;^UTILITY(U,$J,358.3,52488,2)
 ;;=^5002602
 ;;^UTILITY(U,$J,358.3,52489,0)
 ;;=E10.621^^194^2539^6
 ;;^UTILITY(U,$J,358.3,52489,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52489,1,3,0)
 ;;=3^DM Type 1 w/ Diab Foot Ulcer
 ;;^UTILITY(U,$J,358.3,52489,1,4,0)
 ;;=4^E10.621
 ;;^UTILITY(U,$J,358.3,52489,2)
 ;;=^5002616
 ;;^UTILITY(U,$J,358.3,52490,0)
 ;;=E10.622^^194^2539^28
 ;;^UTILITY(U,$J,358.3,52490,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52490,1,3,0)
 ;;=3^DM Type 1 w/ Oth Skin Ulcer
 ;;^UTILITY(U,$J,358.3,52490,1,4,0)
 ;;=4^E10.622
 ;;^UTILITY(U,$J,358.3,52490,2)
 ;;=^5002617
 ;;^UTILITY(U,$J,358.3,52491,0)
 ;;=E10.51^^194^2539^32
 ;;^UTILITY(U,$J,358.3,52491,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52491,1,3,0)
 ;;=3^DM Type 1 w/ Periph Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,52491,1,4,0)
 ;;=4^E10.51
 ;;^UTILITY(U,$J,358.3,52491,2)
 ;;=^5002610
 ;;^UTILITY(U,$J,358.3,52492,0)
 ;;=E10.52^^194^2539^31
 ;;^UTILITY(U,$J,358.3,52492,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52492,1,3,0)
 ;;=3^DM Type 1 w/ Periph Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,52492,1,4,0)
 ;;=4^E10.52
 ;;^UTILITY(U,$J,358.3,52492,2)
 ;;=^5002611
 ;;^UTILITY(U,$J,358.3,52493,0)
 ;;=E11.00^^194^2540^19
 ;;^UTILITY(U,$J,358.3,52493,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52493,1,3,0)
 ;;=3^DM Type 2 w/ Hyperosmolarity w/o NKHHC
 ;;^UTILITY(U,$J,358.3,52493,1,4,0)
 ;;=4^E11.00
 ;;^UTILITY(U,$J,358.3,52493,2)
 ;;=^5002627
 ;;^UTILITY(U,$J,358.3,52494,0)
 ;;=E11.01^^194^2540^18
 ;;^UTILITY(U,$J,358.3,52494,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52494,1,3,0)
 ;;=3^DM Type 2 w/ Hyperosmolarity w/ Coma
 ;;^UTILITY(U,$J,358.3,52494,1,4,0)
 ;;=4^E11.01
 ;;^UTILITY(U,$J,358.3,52494,2)
 ;;=^5002628
 ;;^UTILITY(U,$J,358.3,52495,0)
 ;;=E11.21^^194^2540^7
 ;;^UTILITY(U,$J,358.3,52495,1,0)
 ;;=^358.31IA^4^2
